RT Journal Article
SR Electronic
T1 Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e009474
DO 10.1136/jitc-2024-009474
VO 12
IS 8
A1 Davar, Diwakar
A1 Cavalcante, Ludimila
A1 Lakhani, Nehal
A1 Moser, Justin
A1 Millward, Michael
A1 McKean, Meredith
A1 Voskoboynik, Mark
A1 Sanborn, Rachel E
A1 Grewal, Jaspreet S
A1 Narayan, Ajita
A1 Patnaik, Amita
A1 Gainor, Justin F
A1 Sznol, Mario
A1 Enstrom, Amanda
A1 Blanchfield, Lori
A1 LeBlanc, Heidi
A1 Thomas, Heather
A1 Chisamore, Michael J
A1 Peng, Stanford L
A1 Naumovski, Allison
YR 2024
UL http://jitc.bmj.com/content/12/8/e009474.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.